Why should regulators consider using patient preferences in benefit-risk assessment?

Janine A. Van Til*, Maarten J. IJzerman

*Corresponding author for this work

Research output: Contribution to journalEditorialAcademicpeer-review

37 Citations (Scopus)
3 Downloads (Pure)
Original languageEnglish
Pages (from-to)1-4
Number of pages4
JournalPharmacoEconomics
Volume32
Issue number1
Early online date28 Nov 2013
DOIs
Publication statusPublished - Jan 2014
Externally publishedYes

Cite this